IL199911A0 - 3-cinnolinecarboxamide derivatives and their use for treating cancer - Google Patents

3-cinnolinecarboxamide derivatives and their use for treating cancer

Info

Publication number
IL199911A0
IL199911A0 IL199911A IL19991109A IL199911A0 IL 199911 A0 IL199911 A0 IL 199911A0 IL 199911 A IL199911 A IL 199911A IL 19991109 A IL19991109 A IL 19991109A IL 199911 A0 IL199911 A0 IL 199911A0
Authority
IL
Israel
Prior art keywords
cinnolinecarboxamide
derivatives
treating cancer
cancer
treating
Prior art date
Application number
IL199911A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Zheng Xiaolan
Scott David
Ogoe Claude Afona
Dakin Leslie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39310013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL199911(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Zheng Xiaolan, Scott David, Ogoe Claude Afona, Dakin Leslie filed Critical Astrazeneca Ab
Publication of IL199911A0 publication Critical patent/IL199911A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28Cinnolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL199911A 2007-01-25 2009-07-16 3-cinnolinecarboxamide derivatives and their use for treating cancer IL199911A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88658507P 2007-01-25 2007-01-25
US95157607P 2007-07-24 2007-07-24
PCT/GB2008/000256 WO2008090353A1 (en) 2007-01-25 2008-01-24 3 - cinnolinecarboxamide derivatives and their use for treating cancer

Publications (1)

Publication Number Publication Date
IL199911A0 true IL199911A0 (en) 2010-04-15

Family

ID=39310013

Family Applications (1)

Application Number Title Priority Date Filing Date
IL199911A IL199911A0 (en) 2007-01-25 2009-07-16 3-cinnolinecarboxamide derivatives and their use for treating cancer

Country Status (18)

Country Link
US (2) US7723337B2 (es)
EP (1) EP2118072A1 (es)
JP (1) JP2010500988A (es)
KR (1) KR20090111337A (es)
AR (1) AR065042A1 (es)
AU (1) AU2008208751A1 (es)
BR (1) BRPI0808005A2 (es)
CA (1) CA2675621A1 (es)
CL (1) CL2008000191A1 (es)
CO (1) CO6190614A2 (es)
EC (1) ECSP099539A (es)
IL (1) IL199911A0 (es)
MX (1) MX2009007889A (es)
PE (1) PE20081693A1 (es)
RU (1) RU2009131834A (es)
TW (1) TW200843775A (es)
UY (1) UY30880A1 (es)
WO (1) WO2008090353A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
US20110190272A1 (en) * 2008-05-07 2011-08-04 Astrazeneca Ab Chemical compounds
US9884828B2 (en) 2011-05-23 2018-02-06 Imago Pharmaceuticals, Inc. Substituted cinnolines as inhibitors of LRRK2 kinase activity
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
CN108884084A (zh) * 2016-03-21 2018-11-23 阿斯利康(瑞典)有限公司 噌啉-4-胺化合物及其在治疗癌症中的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621425D0 (en) * 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
DK273689A (da) * 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
JPH04211661A (ja) * 1990-03-28 1992-08-03 Otsuka Pharmaceut Co Ltd キノリン誘導体及び該誘導体を含有する抗潰瘍剤
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4-苯胺基喹唑啉衍生物
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
PL359181A1 (en) 2000-07-07 2004-08-23 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
SE0101675D0 (sv) * 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
GB0322726D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
WO2006124996A2 (en) * 2005-05-17 2006-11-23 Supergen, Inc. Inhibitors of polo-like kinase-1
GB0521563D0 (en) 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
PT2010496E (pt) 2006-04-14 2010-10-13 Astrazeneca Ab 4-anilinoquinolina-3-carboxamidas como inibidores de csf-1r cinase
TW200829555A (en) 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
RU2009131834A (ru) 2011-02-27
EP2118072A1 (en) 2009-11-18
US20110098283A1 (en) 2011-04-28
US7723337B2 (en) 2010-05-25
CO6190614A2 (es) 2010-08-19
AR065042A1 (es) 2009-05-13
MX2009007889A (es) 2009-07-31
ECSP099539A (es) 2009-08-28
CA2675621A1 (en) 2008-07-31
TW200843775A (en) 2008-11-16
CL2008000191A1 (es) 2008-08-22
US20090012084A1 (en) 2009-01-08
UY30880A1 (es) 2008-09-02
BRPI0808005A2 (pt) 2013-07-30
JP2010500988A (ja) 2010-01-14
PE20081693A1 (es) 2009-01-18
AU2008208751A1 (en) 2008-07-31
KR20090111337A (ko) 2009-10-26
WO2008090353A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
HRP20160949T1 (hr) Novi sastavi i metode za liječenje karcinoma
HK1140944A1 (en) Methods and compositions for treating recurrent cancer
EP2125002A4 (en) TREATMENT OF SKIN CANCER
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
HK1143157A1 (en) 4-pyridinone compounds and their use for cancer 4-
ZA201004134B (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
HRP20130642T1 (en) Methods and compositions for treating cancers
IL199911A0 (en) 3-cinnolinecarboxamide derivatives and their use for treating cancer
EP2144888A4 (en) METHODS OF TREATING CANCER
EP2150270A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
HK1151971A1 (en) Compounds for use in the treatment of cancer
ZA200907306B (en) Tetrahydroquinoline derivatives and use of same for treating cancer
GB0707556D0 (en) Treatment for cancer
HK1209754A1 (en) Compounds and methods for the treatment of cancer
GB0710871D0 (en) Cancer treatment
GB0700281D0 (en) Methods and Means for the Treatment of Cancer
GB0700493D0 (en) Cancer treatment
GB0723503D0 (en) Cancer treatment
GB0619271D0 (en) Treating cancer
LT3067054T (lt) Naujos kompozicijos ir būdai vėžiui gydyti
SI3067054T1 (sl) Novi sestavki in postopki za zdravljenje raka
GB0604741D0 (en) Cancer Treatment
GB0618199D0 (en) Cancer treatment
EP2068629A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER